Patents by Inventor John Cameron Bell

John Cameron Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10660947
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 26, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10646557
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: May 12, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty
  • Patent number: 10604741
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: March 31, 2020
    Assignee: TURNSTONE LIMITED PARTNERSHIP
    Inventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
  • Publication number: 20190255160
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Application
    Filed: January 16, 2019
    Publication date: August 22, 2019
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Publication number: 20190240301
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Application
    Filed: January 16, 2019
    Publication date: August 8, 2019
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Patent number: 10363293
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 30, 2019
    Assignee: Turnstone Limited Partnership
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Publication number: 20190216868
    Abstract: Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.
    Type: Application
    Filed: August 9, 2017
    Publication date: July 18, 2019
    Inventors: Almohanad Alkayyal, Rebecca Auer, John Cameron Bell
  • Patent number: 10066214
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: September 4, 2018
    Assignee: Turnstone Limited Partnership
    Inventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
  • Publication number: 20180237753
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Application
    Filed: March 13, 2018
    Publication date: August 23, 2018
    Inventors: Carolina Solange ILKOW, Fabrice LE BOEUF, John Cameron BELL, Jean-Simon DIALLO, Rozanne ARULANANDAM
  • Patent number: 9623096
    Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: April 18, 2017
    Assignee: Celverum Inc.
    Inventors: David Conrad, John Cameron Bell, Harry Atkins
  • Publication number: 20160130563
    Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
    Type: Application
    Filed: June 16, 2014
    Publication date: May 12, 2016
    Inventors: Carolina Solange ILKOW, Fabrice LE BOEUF, John Cameron BELL, Jean-Simon DIALLO, Rozanne ARULANANDAM
  • Publication number: 20160106820
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Application
    Filed: February 20, 2014
    Publication date: April 21, 2016
    Applicants: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC., OTTAWA HOSPITAL RESEARCH INSTITUTE, MCMASTER UNIVERSITY
    Inventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
  • Publication number: 20150320810
    Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
    Type: Application
    Filed: December 20, 2013
    Publication date: November 12, 2015
    Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
  • Publication number: 20150307559
    Abstract: Described herein is an isolated viral particle having a genome that includes open reading frames that encode: Maraba proteins N, P, and L, or variants thereof; as well as Maraba protein M or protein delta 51M, or variants thereof; and a Bahia Grande G protein, a LCMV G protein, or an Ebola G protein. Maraba protein N may have a sequence which includes SEQ ID NO: 1. Maraba protein P may have a sequence which includes SEQ ID NO: 2. Maraba protein L may have a sequence which includes SEQ ID NO: 3. Maraba proteins M and delta 1M may have sequence which include SEQ ID NO: 4 and 5, respectively. Bahia Grande G protein may have a sequence which includes SEQ ID NO: 6. LCMV G protein may have a sequence which includes SEQ ID NO: 7. Ebola G protein may have a sequence which includes SEQ ID NO: 8.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 29, 2015
    Inventors: David STOJDL, John Cameron BELL
  • Publication number: 20110044952
    Abstract: The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection.
    Type: Application
    Filed: November 26, 2008
    Publication date: February 24, 2011
    Applicant: Ottawa Health Research Institute
    Inventors: John Cameron Bell, John Hiscott, Hesham Abdelbary, Thi Lien-Anh Nguyen, Jean-Simon Diallo
  • Publication number: 20040115170
    Abstract: Methods of reducing the viability of a tumor cell, infecting a neoplasm in a mammal, utilizing certain non-naturally occuring viruses are disclosed. Viral reassortants, for example reovirus reassortants, and techniques for identifying PKR-sensitive viruses are also disclosed.
    Type: Application
    Filed: January 8, 2004
    Publication date: June 17, 2004
    Inventors: Earl Garnet Brown, Jean Lutamyo Mbisa, John Cameron Bell, David Francis Stojdl